Gene · 5324
Papers4,340
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
381 to 400 of 4,340
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Emerging Medical Therapies in Rosacea: A Narrative Review. | Dermatol Ther (Heidelb) | 2023 | 37824060 | PubTator, text mining | PubMed |
| Peptides disrupting TM4SF3 interaction with AR or AR-V7 block prostate cancer cell proliferation. | Endocr Oncol | 2023 | 37822366 | PubTator, text mining | PubMed |
| The role of GCNT1 mediated O-glycosylation in aggressive prostate cancer. | Sci Rep | 2023 | 37813880 | PubTator, text mining | PubMed |
| Challenging diagnosis of sarcomatoid hepatic mesothelioma: a case report with review of literature. | Ann Med Surg (Lond) | 2023 | 37811036 | PubTator, text mining | PubMed |
| Acral lentiginous melanoma with multiple bone metastasis: case report. | Pan Afr Med J | 2023 | 37808429 | PubTator, text mining | PubMed |
| Molecular docking analysis of AGTR1 antagonists. | Bioinformation | 2023 | 37808379 | PubTator, text mining | PubMed |
| Pulmonary Tumor Thrombotic Microangiopathy Caused by Esophageal Adenocarcinoma: A Case Report. | Cureus | 2023 | 37791166 | PubTator, text mining | PubMed |
| Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors. | World J Urol | 2023 | 37787941 | PubTator, text mining | PubMed |
| Design, Synthesis, and Biological Evaluation of Novel 3-Cyanopyridone/Pyrazoline Hybrids as Potential Apoptotic Antiproliferative Agents Targeting EGFR/BRAFV600E Inhibitory Pathways. | Molecules | 2023 | 37764362 | PubTator, text mining | PubMed |
| RETRACTED: Neferine Targets the Oncogenic Characteristics of Androgen-Dependent Prostate Cancer Cells via Inducing Reactive Oxygen Species. | Int J Mol Sci | 2023 | 37762540 | PubTator, text mining | PubMed |
| Lactobacillus fermentum Alleviates the Colorectal Inflammation Induced by Low-Dose Sub-Chronic Microcystin-LR Exposure. | Toxins (Basel) | 2023 | 37756005 | PubTator, text mining | PubMed |
| Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients? | Curr Oncol | 2023 | 37754499 | PubTator, text mining | PubMed |
| Cutaneous Syncytial Myoepithelioma with Positive CD34 Immunohistochemical Staining: An Unusual Tumor and a Challenging Diagnosis. | Dermatopathology (Basel) | 2023 | 37754276 | PubTator, text mining | PubMed |
| VISproPT: A high-precision instrument for 3D shape analysis of parabolic trough panels. | Open Res Eur | 2023 | 37744278 | PubTator, text mining | PubMed |
| Pleomorphic adenoma with PLAG1 fusion as an isolated kidney mass: lessons learned from a challenging case. | Histopathology | 2023 | 37743101 | PubTator, text mining | PubMed |
| [Diagnosis and therapy of membranous nephropathy-2023]. | Wien Klin Wochenschr | 2023 | 37728650 | PubTator, text mining | PubMed |
| The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance. | J Transl Med | 2023 | 37726835 | PubTator, text mining | PubMed |
| NKX3.1 Expression Contributes to Epithelial-Mesenchymal Transition of Prostate Cancer Cells. | ACS Omega | 2023 | 37720744 | PubTator, text mining | PubMed |
| Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials. | Cancer Treat Rev | 2023 | 37716332 | PubTator, text mining | PubMed |
| Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial. | Front Oncol | 2023 | 37711193 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5324/papers?page=20